Provided by Tiger Trade Technology Pte. Ltd.

Weight Loss Drugs

1,561.28
-8.4900-0.54%
Number of Gainers:- -
Number of Losers:7
Number of Flat:- -
PE:- -
High:1,579.75
Open:1,579.75
Low:1,559.99
Close:1,569.77
Volume:45.85M
Turnover:4.76B
Market Cap:1.63T
Float Cap:1.56T

Loading ...

Eli Lilly - Taltz and Zepbound Lead to Deeper Improvements in Systemic Inflammation in Both Trials

THOMSON REUTERS
·
Aug 31

New Phase 3B Data on Lilly's Taltz (Ixekizumab) and Zepbound (Tirzepatide) Used Together Showed Improved and Durable Efficacy at One Year in Adults with Psoriatic Disease and Obesity

THOMSON REUTERS
·
Aug 31

Eli Lilly - Taltz and Zepbound Maintain or Improve Disease Activity at Week 52 Versus Taltz Alone

THOMSON REUTERS
·
Aug 31

Eli Lilly: Adverse Events in Participants Treated with Taltz and Zepbound Together were Generally Mild to Moderate

THOMSON REUTERS
·
Aug 31

Lilly to Acquire Merida Biosciences in Deal Worth up to USD 2.88 Billion

Reuters
·
Aug 31

Eli Lilly: Under Terms of Agreement, Lilly Will Acquire Merida and Pay up to $2.875 Bln in Cash

THOMSON REUTERS
·
Aug 31

Lilly to Acquire Merida Biosciences to Advance Treatments for Serious Autoimmune and Allergic Diseases

THOMSON REUTERS
·
Aug 31

Eli Lilly - Deal Expected to Close in Q4 2026 Subject to Regulatory Approvals

THOMSON REUTERS
·
Aug 31

Amgen Says Repatha Cuts Death Risk 20% in High-Risk Patients

MT Newswires Live
·
Aug 31

Amgen Repatha reduces risk of death in high-risk adults for first heart attack

TIPRANKS
·
Aug 31

Amgen's Repatha® Reduces Risk of Death in Patients at High Risk for a First Heart Attack or Stroke

THOMSON REUTERS
·
Aug 31

Pfizer Pivots: New Trials Target Obesity, Cancer, Autoimmune

TIPRANKS
·
Aug 29

Pharma Industry Stares Down Biggest Patent Cliff in Decades

Dow Jones
·
Aug 29

Amgen Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Aug 29

Eli Lilly (LLY) Wins FDA Approval For Mounjaro Heart Risk Reduction

Simply Wall St.
·
Aug 29

Pfizer EVP Cecile Guegan Files Initial Beneficial Ownership Statement

Reuters
·
Aug 29

Pfizer Extends Tucatinib Access With New Continuation Study: What Investors Should Know

TIPRANKS
·
Aug 29

Pfizer Expands Autoimmune Pipeline With New Early-Stage Trial of PF-08154225

TIPRANKS
·
Aug 29

Pfizer Targets China’s Obesity Market With New Phase 3 Berobenatide Trial

TIPRANKS
·
Aug 29

Amgen’s Pediatric Psoriasis Study Wrap-Up: What Apremilast Safety Data Means for Investors

TIPRANKS
·
Aug 29